Publications by authors named "Birgit Fogal"

Claim this Profile
I
Impact of antibody Fc engineering on translational pharmacology, and safety: insights from industry case studies.
Frank R Brennan, J Ryan Polli, Jean Sathish, Melissa Ramones, Babette Wolf, Birgit Fogal

MAbs· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An explorable model of an adverse outcome pathway of cytokine release syndrome related to the administration of immunomodulatory biotherapeutics and cellular therapies.
Alexander Mazein, Oxana Lopata, Kristin Reiche, Katherina Sewald, Miriam Alb, Birgit Fogal

Front Immunol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tailoring the Methods of Conjugation and Characterization for a Replication-Competent, Live, Viral Vector.
Elise Ishida, Richard Dambra, Sally Ye, Steven Anderlot, Andrea Matter, Birgit Fogal

Bioconjug Chem· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel strategies to assess cytokine release mediated by chimeric antigen receptor T cells based on the adverse outcome pathway concept.
Miriam Alb, Kristin Reiche, Michael Rade, Katherina Sewald, Peter Loskill, Birgit Fogal

J Immunotoxicol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges and gaps in immunosafety evaluation of therapeutics: An IQ DruSafe survey.
Mark Collinge, Haley Neff-LaFord, Surekha Akella, Birgit Fogal, Kathryn Fraser

Regul Toxicol Pharmacol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonclinical pharmacokinetics and biodistribution of VSV-GP using methods to decouple input drug disposition and viral replication.
Richard Dambra, Andrea Matter, Kaitlynn Graca, Saeed Salehin Akhand, Saurin Mehta, Birgit Fogal

Mol Ther Methods Clin Dev· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunocompetent cancer-on-chip models to assess immuno-oncology therapy.
Tengku Ibrahim Maulana, Elena Kromidas, Lars Wallstabe, Madalena Cipriano, Miriam Alb, Birgit Fogal

Adv Drug Deliv Rev· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
VHH antibody targeting the chemokine receptor CX3CR1 inhibits progression of atherosclerosis.
Sarah Low, Haixia Wu, Kavita Jerath, Annette Tibolla, Birgit Fogal

MAbs· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Industry experiences with immune-mediated findings in biotherapeutic nonclinical toxicology studies.
Timothy K MacLachlan, Sven Kronenberg, Nikki Marshall, Laura Andrews, Shawn Jay Berens, Birgit Fogal

Regul Toxicol Pharmacol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reperfusion injury intensifies the adaptive human T cell alloresponse in a human-mouse chimeric artery model.
Tai Yi, Birgit Fogal, Zhengrong Hao, Zuzana Tobiasova, Chen Wang

Arterioscler Thromb Vasc Biol· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neutralizing IL-6 reduces human arterial allograft rejection by allowing emergence of CD161+ CD4+ regulatory T cells.
Birgit Fogal, Tai Yi, Chen Wang, Deepak A Rao, Amir Lebastchi

J Immunol· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diazoxide promotes oligodendrocyte precursor cell proliferation and myelination.
Birgit Fogal, Carolyn McClaskey, Sha Yan, Henglin Yan, Scott A Rivkees

PLoS One· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interleukin-1beta: a bridge between inflammation and excitotoxicity?
Birgit Fogal, Sandra J Hewett

J Neurochem· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
System x(c)- activity and astrocytes are necessary for interleukin-1 beta-mediated hypoxic neuronal injury.
Birgit Fogal, Jun Li, Doug Lobner, Louise D McCullough, Sandra J Hewett

J Neurosci· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interleukin-1beta potentiates neuronal injury in a variety of injury models involving energy deprivation.
Birgit Fogal, James A Hewett, Sandra J Hewett

J Neuroimmunol· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis